1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: 
Percentage of tumor and PTRE specimens that were correctly diagnosed by rCBV thresholds measured under various DSC conditions
PLD BLS No BLS
rCBV^a Tumor No. (%) (Total = 21)^b PTRE No. (%)(Total = 15)^c rCBV^a Tumor No. (%) (Total = 21)^b PTRE No. (%) (Total = 15)^c
0.0 1.00–1.06 13 (61.9) 15 (100) 0.93–0.96 13 (61.9) 15 (100)
0.05 1.15–1.16 17 (81.0) 15 (100) 1.09–1.13 15 (71.4) 15 (100)
0.1 1.02–1.03 19 (90.5) 15 (100) 1.14–1.15 18 (85.7) 13 (86.7)
0.15 0.96–0.98 19 (90.5) 14 (93.3) 1.01–1.04 19 (90.5) 13 (80)
0.2 1.22–1.22 17 (81) 15 (100) 1.35–1.38 17 (81.0) 12 (80.0)
0.25 0.99–1.12 19 (90.5) 15 (100) 1.19–1.20 20 (95.2) 13 (86.7)

Note:— PLD indicates preload dosing (mmol/kg); DCS, dynamic susceptibility-weighted contrast–enhanced MR imaging; BLS, baseline subtraction; rCBV, relative cerebral blood volume; PTRE, posttreatment radiation effect.


^a Range of thresholds that maximized accuracy (average of sensitivity and specificity) to diagnose tumor and PTRE specimens under each test condition.


^b Maximum number and percentage of specimens (out of a total of 21) correctly diagnosed by rCBV thresholds.


^c Maximum number and percentage of specimens (out of a total of 15) correctly diagnosed by rCBV thresholds.